Two Phase 3 Trials of Dupilumab versus Placebo in Atopic DermatitisEric L. Simpson, Marius Ardeleanu, Thomas Bieber et al.|New England Journal of Medicine|2016Cited by 2k
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*Andreas Wollenberg, Andrew Blauvelt, Emma Guttman‐Yassky et al.|British Journal of Dermatology|2020Cited by 590
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trialsEmma Guttman‐Yassky, Alan D. Irvine, Henrique D. Teixeira et al.|The Lancet|2021Cited by 538
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic DermatitisEric L. Simpson, Ashish Bansal, Mark Boguniewicz et al.|JAMA Dermatology|2019Cited by 505
Non-lesional Atopic Dermatitis Skin Is Characterized by Broad Terminal Differentiation Defects and Variable Immune AbnormalitiesMayte Suárez‐Fariñas, Emma Guttman‐Yassky|Journal of Allergy and Clinical Immunology|2011Cited by 457